Shares of this multibagger pharma stock under the ‘small-cap’ category hit the 10 percent upper circuit in Wednesday’s trading session after a Bulk Deal took place concerning the company’s equity shares.
With a market capitalization of Rs 1,843.87 crores, the stocks of Jeena Sikho Lifecare Limited opened their trading session on Wednesday hitting the 10 percent upper circuit at Rs 741.70, and are currently trading at the same share price level.
Such sharp stock price movements were witnessed after Societe Generale, one of the leading European financial services groups, sold a stake in the company.
As per the Bulk Deal data available with the National Stock Exchange (NSE), it sold around 2.55 lakh equity shares of the company at an average trade price of Rs 674.43 per equity share.
Apart from Societe Generale, other entities selling a stake in the company include ‘Oregano Life Private Limited’, an existing non-institutional shareholder, selling nearly 2.41 lakh equity shares of the company. On the buying side, Stallion Asset Private Limited bought around 4.93 lakh equity shares of the company at Rs 634.70 per equity share.
The company, reporting its financials half yearly, registered consistent growth as far as the operating revenues and after-tax profits are concerned.
During the recent period, the former rose from Rs 87 crores during the September 2022 quarter to Rs 118 crores during the March 2023 quarter, and the latter, during the same period, more than doubled from Rs 11 crores to Rs 23 crores.
Keeping a purview of one year, the company’s stock has delivered multibagger returns of approximately 345 percent to its shareholders, i.e., if someone had invested Rs 1 lakh into the stock a year ago, it would have converted to Rs 4.45 lakhs.
Founded in 2009, Jeena Sikho Lifecare Limited is engaged in the business of trading ayurvedic medicines in India. The company offers Ayurvedic products, operating around 150 clinics, ayurvedic therapies, and also provides health care services.
Written by Amit Madnani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
